Physician profile
Joanne E Langton
NPI 1255375465
$15,995.74
in general payments reported to CMS, 2019-2025
42 companies · $1,897 in 2025
The $1,897 reported for 2025 was more than what 76% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,314 · 2020: $1,807 · 2021: $2,561 · 2022: $2,479 · 2023: $2,189 · 2024: $1,748 · 2025: $1,897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,834.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $3,095.36 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $2,025.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic Minimed, INC. | $1,710.30 | 2019-2020 | |
| Abbott Laboratories | $1,048.11 | 2019-2025 | Freestyle Libre 3 |
| Abbvie INC. | $755.83 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $740.34 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $629.92 | 2019-2023 | Farxiga |
| Dexcom, INC. | $616.69 | 2019-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $603.13 | 2019-2025 | Omnipod |
| Medtronic, INC. | $525.45 | 2021-2025 | Minimed 780g, Minimed 770g, Intellis Adaptivestim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $509.98 | 2019-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $502.92 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Amgen INC. | $388.25 | 2019-2025 | Tepezza, Evenity, Prolia |
| Corcept Therapeutics | $351.61 | 2019-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $227.45 | 2021-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $209.98 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $202.29 | 2019-2021 | |
| Lifescan, INC. | $186.93 | 2019-2022 | |
| Mannkind Corporation | $183.05 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $149.47 | 2022-2025 | Unithroid |
| Sequel Med Tech, LLC | $135.62 | 2025 | Twiist |
| Janssen Pharmaceuticals, INC | $126.86 | 2019-2023 | Xarelto |
| Tandem Diabetes Care, INC. | $123.87 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Currax Pharmaceuticals LLC | $102.54 | 2021-2023 | Contrave |
| Zealand Pharma US, INC. | $94.17 | 2020-2021 | |
| Amarin Pharma, INC. | $86.83 | 2021 | |
| Shire North American Group INC | $84.08 | 2019 | |
| Glaxosmithkline, LLC. | $81.19 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Clarus Therapeutics INC. | $78.46 | 2021 | |
| Kyowa Kirin, INC. | $64.33 | 2022-2024 | Crysvita |
| Neurocrine Biosciences, INC. | $45.22 | 2025 | |
| Horizon Therapeutics Plc | $43.41 | 2023 | Tepezza |
| Bigfoot Biomedical INC | $43.22 | 2022 | |
| Opko Pharmaceuticals, LLC | $35.85 | 2022 | |
| Esperion Therapeutics, INC. | $33.26 | 2020-2021 | |
| Cequr Corporation | $32.45 | 2024 | Cequr Simplicity |
| Antares Pharma, INC. | $30.42 | 2024-2025 | Xyosted |
| Ascendis Pharma Endocrinology INC | $24.10 | 2025 | Yorvipath |
| Pfizer INC. | $20.27 | 2023 | |
| Alexion Pharmaceuticals, INC. | $19.38 | 2019 | |
| Acella Pharmaceuticals, LLC | $14.28 | 2025 | NP Thyroid 60 |
| Grt US Holding, INC. | $13.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanne Langton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.